The Global Therapeutic Landscape of Hypertrophic Cardiomyopathy

1
Hypertrophic Cardiomyopathy - Pipeline Review H1
2016
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Hypertrophic Cardiomyopathy - Pipeline Review,
  H1 2016, provides an overview of the
  Hypertrophic Cardiomyopathy pipeline landscape.
• The report provides comprehensive information on
  the therapeutics under development for
  Hypertrophic Cardiomyopathy, complete with
  analysis by stage of development, drug target,
  mechanism of action (MoA), route of
  administration (RoA) and molecule type. The
  report also covers the descriptive
  pharmacological action of the therapeutics, its
  complete research and development history and
  latest news and press releases. Additionally, the
  report provides an overview of key players
  involved in therapeutic development for
  Hypertrophic Cardiomyopathy and features dormant
  and discontinued projects.
• Global Markets Directs report features
  investigational drugs from across globe covering
  over 20 therapy areas and nearly 3,000
  indications. The report is built using data and
  information sourced from Global Markets Directs
  proprietary databases, company/university
  websites, clinical trial registries, conferences,
  SEC filings, investor presentations and featured
  press releases from company/university sites and
  industry-specific third party sources. Drug
  profiles featured in the report undergoes
  periodic review following a stringent set of
  processes to ensure that all the profiles are
  updated with the latest set of information.
  Additionally, various dynamic tracking processes
  ensure that the most recent developments are
  captured on a real time basis.
• The report helps in identifying and tracking
  emerging players in the market and their
  portfolios, enhances decision making capabilities
  and helps to create effective counter strategies
  to gain competitive advantage.
• Strategic Focus Report http//www.researchbeam.co
  m/hypertrophic-cardiomyopathy-pipeline-review-h1-2
  016-market

3


Report Overview

• Scope
• - The report provides a snapshot of the global
  therapeutic landscape of Hypertrophic
  Cardiomyopathy
• - The report reviews pipeline therapeutics for
  Hypertrophic Cardiomyopathy by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources
• - The report covers pipeline products based on
  various stages of development ranging from
  pre-registration till discovery and undisclosed
  stages
• - The report features descriptive drug profiles
  for the pipeline products which includes, product
  description, descriptive MoA, RD brief,
  licensing and collaboration details other
  developmental activities
• - The report reviews key players involved
  Hypertrophic Cardiomyopathy therapeutics and
  enlists all their major and minor projects
• Reasons to buy
• - Gain strategically significant competitor
  information, analysis, and insights to formulate
  effective RD strategies
• - Identify emerging players with potentially
  strong product portfolio and create effective
  counter-strategies to gain competitive advantage
• - Identify and understand important and diverse
  types of therapeutics under development for
  Hypertrophic Cardiomyopathy
• - Identify potential new clients or partners in
  the target demographic

4


Table of Contents
Table of Contents 2 List of Tables 4 List of
Figures 4 Introduction 5 Global Markets Direct
Report Coverage 5 Hypertrophic Cardiomyopathy
Overview 6 Therapeutics Development 7 Pipeline
Products for Hypertrophic Cardiomyopathy -
Overview 7 Pipeline Products for Hypertrophic
Cardiomyopathy - Comparative Analysis
8 Hypertrophic Cardiomyopathy - Therapeutics
under Development by Companies 9 Hypertrophic
Cardiomyopathy - Therapeutics under Investigation
by Universities/Institutes 10 Hypertrophic
Cardiomyopathy - Pipeline Products Glance
11 Clinical Stage Products 11 Early Stage
Products 12 Hypertrophic Cardiomyopathy -
Products under Development by Companies
13 Hypertrophic Cardiomyopathy - Products under
Investigation by Universities/Institutes
14 Hypertrophic Cardiomyopathy - Companies
Involved in Therapeutics Development 15 Gilead
Sciences, Inc. 15 Heart Metabolics Limited
16 miRagen Therapeutics, Inc. 17 MyoKardia, Inc.
18 Hypertrophic Cardiomyopathy - Therapeutics
Assessment 19 Assessment by Monotherapy Products
19
5


Report Ordering
Report Name Hypertrophic
Cardiomyopathy - Pipeline Review H1
2016
Product Price
User Price
Single User US 1700
Site User US 4000
Global User US 6000
To View Sample or Purchase Report
6



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/hypertrophic-cardiomyo
pathy-pipeline-review-h1-2016-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com